Loading
HPLC blend ratio + LC-MS identity for each peptide (DAC vs no-DAC). The starting receipt — public COA + accession #.
Blend ID + Net Peptide Content per peptide + TFA / acetate residual. The injectable-receipt panel.
Plus USP <85> endotoxin, USP <71> sterility, heavy metals, residual solvents. The injectable-grade COA.
CJC-1295 with DAC (Drug Affinity Complex, sometimes called CJC-1295-DAC or just CJC-1295) carries a fatty-acid maleimide modification that binds albumin and extends the in-vivo half-life to about 6-8 days. CJC-1295 without DAC (also called Mod GRF 1-29) has the same sequence minus the DAC modification, with a half-life of ~30 minutes. These are very different molecules pharmacologically — DAC supports once-weekly dosing, no-DAC requires multiple daily doses. Vials labeled just 'CJC-1295' without specifying are ambiguous; LC-MS tells you which one is actually in the vial.
Field data: across ~200 CJC-Ipa blend submissions we've tested, labeled 2:1 CJC:Ipa actually measures 3.5:1 to 5:1 in roughly 60 % of cases. Manufacturers under-fill the more expensive peptide. The blend ratio assay measures actual mg of each peptide; pricing then makes sense relative to what's actually in the vial.
Yes. Single submission, single chromatogram, both peptides quantified separately. We tune the HPLC gradient to resolve any co-elution between the two peptides — both report independent purity %, retention time, and MS identity on the same COA.
Single 5 mg blended vial (whatever the combined labeled mass is). We re-use the dissolved material across HPLC blend-ratio, LC-MS dual identity, and NPC assays. For Full Disclosure, send two additional vials for sterility and endotoxin (destructive).
Both. Pre-mixed blended vials run on a single dual-component HPLC method. Separate vials (one CJC + one Ipa, labeled as a 'stack') run individually with each peptide on its own panel. Pricing matches: blend = single $249 / $599 / $999; separates = two individual peptide-panel orders.
Blend ratio, by a meaningful margin. Most submissions show CJC purity 92-97 % and Ipa purity 89-95 %, which is within reasonable for research-grade material. But the blend ratio gap (labeled 2:1 vs actual 4:1) means dose calculations are off by 100 % on the Ipa side. That's the bigger practical problem if dose accuracy matters.
Blend ratio, dual identity, NPC per peptide, endotoxin, sterility — Houston bench, public COA, transparent pricing.